Abaloparatide and paclitaxel combination therapy Improves bone volume and tumor burden in Bone-Metastatic breast cancer

Key Points

• The study aims to evaluate the effects of abaloparatide and paclitaxel combination therapy on bone volume and tumor burden in bone-metastatic breast cancer.
• Conducted experiments using mice with established breast cancer skeletal metastases.
• Administered combination therapy of abaloparatide and paclitaxel to the experimental group.
• Compared outcomes of bone volume and tumor burden between combination therapy and control groups.
• The combination therapy significantly reduced tumor burden compared to control.
• Bone volume increased in the group receiving both abaloparatide and paclitaxel.
• Abaloparatide alone did not show any significant impact on either tumor burden or bone volume.